ResultsIQ

ResultsIQ › Latest results › Gaudium IVF and Women Health Limited

Gaudium IVF and Women Health Limited Q2 FY27 results press release summary

NSE: GAUDIUMIVF · BSE: 544709

Results press release of 12 Nov 2026, summarised by AI from the filing.

Gaudium IVF Q2 FY27 revenue ₹37.4 cr, up 17.9% YoY, with EBITDA margin at 36.0% as two new hubs began operations.

Key takeaways

  1. Q2 revenue Revenue ₹37.4 cr, up 17.9% YoY, on seasonally stronger volumes at mature hubs and initial South Extension contribution.
  2. H2 outlook Management expects a stronger second half as mature hubs grow, new hubs scale and more centres come on stream.
  3. Margin drag Q2 EBITDA margin fell to 36.0% from 43.4% on one-off rollout costs and fixed costs of new hubs.
  4. Margin risk New hubs carry high fixed costs ahead of patient volumes, weighing on consolidated margins until each hub matures.

Original filing on BSE

Gaudium IVF and Women Health Limited Q2 FY27 results

As filed: Revenue ₹37.4 cr, EBITDA ₹13.5 cr, PAT ₹9.4 cr, EBITDA margin 36.0%.

Not scored. No consolidated results for the same quarter last year to compare yet (consolidated revenue ₹37.4 cr). Scored once a year-earlier consolidated quarter exists.

Earlier results and the share price after them

  • Q1 FY27: Revenue ₹19.4 cr, EBITDA ₹2.4 cr, PAT ₹1.8 cr, EBITDA margin 12.5%. Not scored. Too small to score: quarter revenue ₹19.4 cr is below the ₹20.0 cr minimum. On a base this small, percentage changes say little. Share price after the results: −6.4% in 29 days (Nifty 500: −3.3%).
  • Q4 FY26: Revenue ₹30.4 cr, EBITDA ₹12.2 cr, PAT ₹8.4 cr, EBITDA margin 40.1%. Not scored. No consolidated results for the same quarter last year to compare yet (consolidated revenue ₹30.4 cr). Scored once a year-earlier consolidated quarter exists. Share price after the results: −7.0% in 28 days (Nifty 500: +0.6%).
  • Q3 FY26: Revenue ₹24.5 cr, EBITDA ₹6.6 cr, PAT ₹3.6 cr, EBITDA margin 26.7%. Not scored. No consolidated results for the same quarter last year to compare yet (consolidated revenue ₹24.5 cr). Scored once a year-earlier consolidated quarter exists. Share price after the results: +2.2% in 30 days (Nifty 500: +4.3%).

Past price moves after results do not indicate future moves. Not a recommendation.

Gaudium IVF and Women Health Limited earnings call, investor presentation and press release summaries

Figures from the company's filings with NSE and BSE. Not investment advice.